BIOMAT Database Logo BIOMAT Database Logo

[PDE-5 inhibitors: patients preferences]. 2017

E A Efremov, and E V Kasatonova, and Ya I Melnik, and A A Nikushina
Department of Andrology and Human Reproduction, N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology branch of NMRRC of Minzdrav of Russia, Moscow, Russia.

To date, multidisciplinary approach is commonly used to treat erectile dysfunction (ED), and the first line of ED pharmacotherapy, despite its multiple causes, is phosphodiesterase inhibitors of type 5 (PDE-5). They are considered an effective and well tolerated treatment option [1-4]. Concurrently, sildenafil has the largest evidence base for efficacy and safety [5]. The satisfaction of patients with ED therapy is a complex and personal matter, and there are no clearly established and reliable criteria for showing preferences when choosing a PDE-5. Adherence of patients to the PDE-5 therapy is determined not only by the erectile response and side effects, but also by how well the treatment meets the needs and expectations of patients and how it affects the relationship between the partners. This review examines the tolerability and efficacy of the various types of PDE-5 available for treating ED, with a special emphasis on the patient's preferences, and in particular on the new sildenafil orodispersible films. As an alternative route of drug administration, films quickly dissolve in the mouth [6] and have several advantages, improve sexual health and the sense of psychological well-being of patients and their partners.

UI MeSH Term Description Entries
D007172 Erectile Dysfunction The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction. Impotence,Male Impotence,Male Sexual Impotence,Dysfunction, Erectile,Impotence, Male,Impotence, Male Sexual,Sexual Impotence, Male
D008297 Male Males
D004304 Dosage Forms Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect. Dosage Form,Form, Dosage,Forms, Dosage
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068677 Sildenafil Citrate A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION. 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate,Acetildenafil,Desmethyl Sildenafil,Desmethylsildenafil,Homosildenafil,Hydroxyhomosildenafil,NCX-911,Revatio,Sildenafil,Sildenafil Lactate,Sildenafil Nitrate,UK 92480-10,UK-92,480-10,Viagra,Citrate, Sildenafil,Lactate, Sildenafil,NCX 911,NCX911,Nitrate, Sildenafil,Sildenafil, Desmethyl,UK 92,480 10,UK 92480 10,UK 9248010
D017060 Patient Satisfaction The degree to which the individual regards the health care service or product or the manner in which it is delivered by the provider as useful, effective, or beneficial. Satisfaction, Patient
D057240 Patient Preference Individual's expression of desirability or value of one course of action, outcome, or selection in contrast to others. Patient Preferences,Preference, Patient,Preferences, Patient
D058986 Phosphodiesterase 5 Inhibitors Compounds that specifically inhibit PHOSPHODIESTERASE 5. PDE-5 Inhibitor,PDE5 Inhibitor,Phosphodiesterase 5 Inhibitor,Phosphodiesterase Type 5 Inhibitor,PDE-5 Inhibitors,PDE5 Inhibitors,Phosphodiesterase Type 5 Inhibitors,5 Inhibitor, Phosphodiesterase,Inhibitor, PDE-5,Inhibitor, PDE5,Inhibitor, Phosphodiesterase 5,Inhibitors, PDE-5,Inhibitors, PDE5,Inhibitors, Phosphodiesterase 5,PDE 5 Inhibitor,PDE 5 Inhibitors
D060728 Reproductive Health The state of the REPRODUCTIVE SYSTEM when functioning optimally without evidence of disease, disorders, or deficiencies. Health, Reproductive

Related Publications

E A Efremov, and E V Kasatonova, and Ya I Melnik, and A A Nikushina
PDE-5 inhibitors: clinical points.
January 2015, Current drug targets,
E A Efremov, and E V Kasatonova, and Ya I Melnik, and A A Nikushina
An update on the PDE-5 inhibitors (PDE-5i).
January 2003, Journal of andrology,
E A Efremov, and E V Kasatonova, and Ya I Melnik, and A A Nikushina
Epistaxis after PDE-5 inhibitors misuse.
January 2006, International journal of impotence research,
E A Efremov, and E V Kasatonova, and Ya I Melnik, and A A Nikushina
The PDE-5 inhibitors and psychiatry.
January 2006, Journal of psychiatric practice,
E A Efremov, and E V Kasatonova, and Ya I Melnik, and A A Nikushina
[How effective are PDE-5 inhibitors?].
April 2003, Der Urologe. Ausg. A,
E A Efremov, and E V Kasatonova, and Ya I Melnik, and A A Nikushina
Therapy of ED: PDE-5 Inhibitors.
January 2004, Endocrine,
E A Efremov, and E V Kasatonova, and Ya I Melnik, and A A Nikushina
PDE-5 inhibitors: spoilt for choice.
August 2006, International journal of clinical practice,
E A Efremov, and E V Kasatonova, and Ya I Melnik, and A A Nikushina
Preoperative administration of PDE-5 Inhibitors.
March 2009, Journal of clinical anesthesia,
E A Efremov, and E V Kasatonova, and Ya I Melnik, and A A Nikushina
PDE-5 Inhibitors for BPH-Associated LUTS.
January 2015, Current drug targets,
E A Efremov, and E V Kasatonova, and Ya I Melnik, and A A Nikushina
Phosphodiesterase-5 (PDE-5) Inhibitors and Ototoxicity: A Systematic Review.
March 2019, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology,
Copied contents to your clipboard!